HDAC6 Inhibitors
Santa Cruz Biotechnology now offers a broad range of HDAC6 Inhibitors. Histone deacetylase proteins (HDACs) are a class of enzymes that remove acetyl groups (O=C-CH3) from an <ε>-N-acetyl lysine amino acid on a histone, allowing histones to wrap DNA more tightly. The deacetylation of histones is associated with transcriptional silencing. Histone deacetylase inhibitors (HDIs) have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptic. HDIs are studied as a treatment for neurodegenerative diseases and have a potential for cancer therapy. HDAC6 Inhibitors offered by Santa Cruz inhibit HDAC6 and, in some cases, other chromatin remodeling and transcription regulation related proteins. View detailed HDAC6 Inhibitor specifications, including HDAC6 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 11 to 19 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BATCP | 787549-23-9 | sc-252405 | 2 mg | $109.00 | ||
BATCP serves as a selective inhibitor of HDAC6, distinguished by its unique structural conformation that facilitates specific interactions with the enzyme's catalytic domain. This compound engages in hydrophobic interactions and electrostatic attractions, enhancing its binding efficacy. Its reaction kinetics reveal a reversible inhibition pattern, allowing for dynamic modulation of histone acetylation. Furthermore, BATCP's influence on protein-protein interactions underscores its role in cellular homeostasis and regulatory networks. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin is an HDAC inhibitor that may target HDAC6 among other HDACs. | ||||||
PCI-24781 | 783355-60-2 | sc-364565 sc-364565A | 5 mg 50 mg | $186.00 $1357.00 | 1 | |
PCI-24781 is a selective HDAC6 inhibitor characterized by its ability to disrupt the enzyme's active site through specific hydrogen bonding and hydrophobic contacts. This compound exhibits a unique binding affinity that alters the conformational dynamics of HDAC6, influencing its enzymatic activity. The kinetics of PCI-24781 reveal a competitive inhibition mechanism, allowing for precise modulation of acetylation states in target proteins, thereby impacting cellular signaling pathways and protein stability. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is a pan-HDAC inhibitor and may inhibit HDAC6 activity or expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 primarily targets class I HDACs but may have effects on HDAC6 as well. | ||||||
Nexturastat A | 1403783-31-2 | sc-478176 | 1 mg | $330.00 | ||
Nexturastat A is a selective HDAC6 inhibitor, down-regulating its activity. | ||||||
ACY-1215 | 1316214-52-4 | sc-507455 | 25 mg | $110.00 | ||
ACY-241 is an HDAC6-selective inhibitor, specifically targeting HDAC6. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $99.00 $536.00 | 1 | |
CI 994 is an HDAC inhibitor which might have effects on HDAC6. | ||||||
PPM-18 | 65240-86-0 | sc-203216 | 10 mg | $220.00 | ||
PPM-18 is a selective inhibitor of HDAC6, distinguished by its unique ability to engage in π-π stacking interactions with aromatic residues within the enzyme's active site. This compound alters the electrostatic environment, enhancing binding affinity and promoting a conformational shift that stabilizes the inactive form of HDAC6. Kinetic studies indicate a non-competitive inhibition profile, allowing for nuanced regulation of histone acetylation and downstream effects on gene expression and cellular processes. | ||||||